Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

Dedicated two-stent technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: the EES-bifurcation study.

Kherada NI, Sartori S, Tomey MI, Mennuni MG, Meelu OA, Roy S, Mohanty BD, Baber U, Pyo R, Kovacic JC, Sweeny J, Moreno P, Krishnan P, Dangas GD, Mehran R, Sharma SK, Kini AS.

Int J Cardiol. 2014 Jun 1;174(1):13-7. doi: 10.1016/j.ijcard.2014.03.029. Epub 2014 Mar 15.

PMID:
24731975
2.

Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.

JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.

3.

Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study.

Džavík V, Kaul U, Guagliumi G, Chevalier B, Smits PC, Stuteville M, Li D, Sudhir K, Grube E.

Catheter Cardiovasc Interv. 2013 Sep 1;82(3):E163-72. doi: 10.1002/ccd.24775. Epub 2013 May 3.

PMID:
23225766
4.

Resolute zotarolimus-eluting stent to treat bifurcated lesions according to the provisional technique: a procedural performance comparison with sirolimus- and everolimus-eluting stents.

Burzotta F, Trani C, Talarico GP, Tommasino A, Todaro D, Coluccia V, Pirozzolo G, Niccoli G, Leone AM, Porto I, Schiavoni G, Crea F.

Cardiovasc Revasc Med. 2013 May-Jun;14(3):122-7. doi: 10.1016/j.carrev.2013.01.002. Epub 2013 Feb 27.

PMID:
23453789
5.

Approach to coronary bifurcation lesions using the everolimus-eluting stent: comparison between a simple strategy and a complex strategy with T-stenting.

Ruiz-Salmerón RJ, Valenzuela LF, Pérez I, Fuentes M, Rodríguez-Leiras S, Vizcaíno M, Carrascosa C, Marcos F.

Rev Esp Cardiol (Engl Ed). 2013 Aug;66(8):636-43. doi: 10.1016/j.rec.2013.03.005. Epub 2013 Jun 6.

PMID:
24776332
6.

Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach.

Burzotta F, Trani C, Todaro D, Mariani L, Talarico GP, Tommasino A, Giammarinaro M, Niccoli G, Porto I, Leone AM, Mongiardo R, Mazzari MA, Schiavoni G, Crea F.

JACC Cardiovasc Interv. 2011 Mar;4(3):327-35. doi: 10.1016/j.jcin.2010.12.005.

7.

5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW.

JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13.

8.

Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.

Kervinen K, Niemelä M, Romppanen H, Erglis A, Kumsars I, Maeng M, Holm NR, Lassen JF, Gunnes P, Stavnes S, Jensen JS, Galløe A, Narbute I, Sondore D, Christiansen EH, Ravkilde J, Steigen TK, Mannsverk J, Thayssen P, Hansen KN, Helqvist S, Vikman S, Wiseth R, Aarøe J, Jokelainen J, Thuesen L; Nordic PCI Study Group.

JACC Cardiovasc Interv. 2013 Nov;6(11):1160-5. doi: 10.1016/j.jcin.2013.06.009.

9.

Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.

Laynez A, Sardi G, Hauville C, Barbash IM, Pakala R, Torguson R, Xue Z, Satler LF, Pichard AD, Waksman R.

Catheter Cardiovasc Interv. 2013 Apr;81(5):759-65. doi: 10.1002/ccd.24438. Epub 2012 Apr 23.

PMID:
22488756
10.

4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).

Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S; RESOLUTE All-Comers Investigators.

J Am Coll Cardiol. 2014 Apr 29;63(16):1617-25. doi: 10.1016/j.jacc.2013.12.036. Epub 2014 Feb 13.

11.

Randomized study comparing everolimus- and sirolimus-eluting stents in patients with bifurcation lesions treated by provisional side-branch stenting.

Pan M, Medina A, Suárez de Lezo J, Romero M, Segura J, Martín P, Suárez de Lezo J, Hernandez E, Mazuelos F, Ojeda S.

Catheter Cardiovasc Interv. 2012 Dec 1;80(7):1165-70. doi: 10.1002/ccd.24281. Epub 2012 Apr 17.

PMID:
22511299
13.

Comparison of provisional 1-stent and 2-stent strategies in diabetic patients with true bifurcation lesions: the EES bifurcation study.

Meelu OA, Tomey MI, Sartori S, Kherada N, Mennuni MG, Theodoropoulos KN, Sayeneni S, Baber U, Pyo RT, Kovacic JC, Moreno P, Krishnan P, Mehran R, Dangas GD, Kini AS, Sharma SK.

J Invasive Cardiol. 2014 Dec;26(12):619-23.

14.

Serial intravascular ultrasound analysis of complex bifurcation coronary lesions treated with the Tryton Bifurcation Stent in conjunction with an everolimus-eluting stent: IUVANT (Intravascular Ultrasound Evaluation of Tryton Stent) study.

Bartorelli AL, Trabattoni D, Almonacid A, Fabbiocchi F, Montorsi P, Galli S, Grancini L, Ravagnani P, Mintz GS, Kaplan AV, Popma JJ, Maehara A.

Catheter Cardiovasc Interv. 2015 Mar;85(4):544-53. doi: 10.1002/ccd.25629. Epub 2014 Aug 28.

PMID:
25115944
15.

The role of everolimus-eluting and resolute zotarolimus-eluting stents in the treatment of coronary bifurcations.

Ferrarello S, Costopoulos C, Latib A, Naganuma T, Sticchi A, Figini F, Basavarajaiah S, Carlino M, Chieffo A, Montorfano M, Kawaguchi M, Naim C, Giannini F, Colombo A.

J Invasive Cardiol. 2013 Sep;25(9):436-40.

17.

Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.

Almalla M, Schröder J, Pross V, Marx N, Hoffmann R.

Catheter Cardiovasc Interv. 2014 May 1;83(6):881-7. doi: 10.1002/ccd.25072. Epub 2013 Jul 3.

PMID:
23765557
18.

Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.

Simsek C, Räber L, Magro M, Boersma E, Onuma Y, Stefanini GG, Zanchin T, Kalesan B, Wenaweser P, Jüni P, van Geuns RJ, van Domburg RT, Windecker S, Serruys PW.

Int J Cardiol. 2013 Dec 5;170(1):36-42. doi: 10.1016/j.ijcard.2013.10.006. Epub 2013 Oct 12.

PMID:
24196314
19.

Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.

Harjai KJ, Kondareddy S, Pinkosky B, Harjai N, Orshaw P, Boura J.

J Interv Cardiol. 2013 Apr;26(2):153-62. doi: 10.1111/j.1540-8183.2013.12016.x. Epub 2013 Jan 31.

PMID:
23363439
20.

Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.

Kitabata H, Loh JP, Pendyala LK, Badr S, Dvir D, Barbash IM, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.

Am J Cardiol. 2013 Oct 15;112(8):1093-8. doi: 10.1016/j.amjcard.2013.05.054. Epub 2013 Jul 2.

PMID:
23827397

Supplemental Content

Support Center